CoChat
Sign Up
Cited by 158

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD

Kirkeby, Agnete, Nelander, Jenny, Hoban, Deirdre B., Rogelius, Nina, Bjartmarz, Hjálmar, Storm, Petter, Fiorenzano, Alessandro, Adler, Andrew F., Vale, Shelby, Mudannayake, Janitha, Zhang, Yu, Cardoso, Tiago, Mattsson, Bengt, Landau, Anne M., Glud, Andreas N., Sørensen, Jens C., Lillethorup, Thea P., Lowdell, Mark, Carvalho, Carla, Bain, Owen, van Vliet, Trinette, Lindvall, Olle, Björklund, Anders, Harry, Bronwen, Cutting, Emma, Widner, Håkan, Paul, Gesine, Barker, Roger A., Parmar, Malin·2023·Cell Stem Cell
DOI 10.1016/j.stem.2023.08.014
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stem.2023.08.014

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
Figure 1 Manufacturing and quality control of STEM-PD
Figure 1 Manufacturing and quality control of STEM-PDCC-BY · From the PDF
Figure 2 GLP safety study for toxicity, tumorigenicity, and biodistribution
Figure 2 GLP safety study for toxicity, tumorigenicity, and biodistributionCC-BY · From the PDF
Image 4
CC-BY · From the PDF
Figure 4 Batch-to-batch comparability on in vivo efficacy
Figure 4 Batch-to-batch comparability on in vivo efficacyCC-BY · From the PDF
Figure 5 Testing of R-L device compatibility with STEM-PD cells in vitro and in minipig
Figure 5 Testing of R-L device compatibility with STEM-PD cells in vitro and in minipigCC-BY · From the PDF
Image 7
CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. Kehagia, 2013, Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis, Neurodegener. Dis., 11, 79, 10.1159/000341998 · DOI
  2. Obeso, 2000, The evolution and origin of motor complications in Parkinson's disease, Neurology, 55, S13
  3. Barker, 2023, Restorative cell and gene therapies for Parkinson's disease, Handb. Clin. Neurol., 193, 211, 10.1016/B978-0-323-85555-6.00012-6 · DOI
  4. Lindvall, 1990, Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease, Science, 247, 574, 10.1126/science.2105529 · DOI
  5. Lindvall, 1994, Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease, Ann. Neurol., 35, 172, 10.1002/ana.410350208 · DOI
  6. Freed, 2001, Transplantation of embryonic dopamine neurons for severe Parkinson's disease, N. Engl. J. Med., 344, 710, 10.1056/NEJM200103083441002 · DOI · Paper page
  7. Kordower, 1997, Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery, Exp. Neurol., 144, 41, 10.1006/exnr.1996.6386 · DOI
  8. Mendez, 2005, Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease, Brain, 128, 1498, 10.1093/brain/awh510 · DOI
  9. Piccini, 2005, Factors affecting the clinical outcome after neural transplantation in Parkinson's disease, Brain, 128, 2977, 10.1093/brain/awh649 · DOI
  10. Kefalopoulou, 2014, Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports, JAMA Neurol., 71, 83, 10.1001/jamaneurol.2013.4749 · DOI
  11. Olanow, 2003, A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease, Ann. Neurol., 54, 403, 10.1002/ana.10720 · DOI · Paper page
  12. Barker, 2013, Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease, Lancet Neurol., 12, 84, 10.1016/S1474-4422(12)70295-8 · DOI
  13. Barker, 2019, Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease, Nat. Med., 25, 1045, 10.1038/s41591-019-0507-2 · DOI · Paper page
  14. Kikuchi, 2011, Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease, J. Parkinsons Dis., 1, 395, 10.3233/JPD-2011-11070 · DOI
  15. Kirkeby, 2017, Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson's disease, Cell Stem Cell, 20, 135, 10.1016/j.stem.2016.09.004 · DOI
  16. Kriks, 2011, Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease, Nature, 480, 547, 10.1038/nature10648 · DOI
  17. Grealish, 2014, Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease, Cell Stem Cell, 15, 653, 10.1016/j.stem.2014.09.017 · DOI
  18. Doi, 2020, Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease, Nat. Commun., 11, 10.1038/s41467-020-17165-w · DOI · Paper page
  19. Kim, 2021, Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use, Cell Stem Cell, 28, 343, 10.1016/j.stem.2021.01.005 · DOI · Paper page
  20. Piao, 2021, Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01, Cell Stem Cell, 28, 217, 10.1016/j.stem.2021.01.004 · DOI · Paper page
  21. Nolbrant, 2017, Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation, Nat. Protoc., 12, 1962, 10.1038/nprot.2017.078 · DOI
  22. Bolon, 2013, STP position paper: recommended practices for sampling and processing the nervous system (brain, spinal cord, nerve, and eye) during nonclinical general toxicity studies, Toxicol. Pathol., 41, 1028, 10.1177/0192623312474865 · DOI
  23. Politis, 2011, Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio, Mov. Disord., 26, 1997, 10.1002/mds.23743 · DOI
  24. Politis, 2010, Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants, Sci. Transl. Med., 2, 38ra46, 10.1126/scitranslmed.3000976 · DOI
  25. Rath, 2013, Survival and functional restoration of human fetal ventral mesencephalon following transplantation in a rat model of Parkinson's disease, Cell Transplant., 22, 1281, 10.3727/096368912X654984 · DOI
  26. Li, 2016, Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain, Proc. Natl. Acad. Sci. USA, 113, 6544, 10.1073/pnas.1605245113 · DOI · Paper page
  27. Widner, 1992, Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), N. Engl. J. Med., 327, 1556, 10.1056/NEJM199211263272203 · DOI
  28. Lindvall, 1989, Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up, Arch. Neurol., 46, 615, 10.1001/archneur.1989.00520420033021 · DOI
  29. Hardman, 2002, Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei, J. Comp. Neurol., 445, 238, 10.1002/cne.10165 · DOI
  30. Kirkeby, 2017, Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD), Prog. Brain Res., 230, 165, 10.1016/bs.pbr.2016.11.011 · DOI
  31. Ma, 2010, Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes, J. Nucl. Med., 51, 7, 10.2967/jnumed.109.066811 · DOI · Paper page
  32. Takahashi, 2020, iPS cell-based therapy for Parkinson's disease: A Kyoto trial, Regen. Ther., 13, 18, 10.1016/j.reth.2020.06.002 · DOI · Paper page
  33. Cardoso, 2018, Target-specific forebrain projections and appropriate synaptic inputs of hESC-derived dopamine neurons grafted to the midbrain of parkinsonian rats, J. Comp. Neurol., 526, 2133, 10.1002/cne.24500 · DOI
  34. Elabi, 2022, Human embryonic stem cell-derived dopaminergic grafts alleviate L-dopa induced dyskinesia, J. Parkinsons Dis., 12, 1881, 10.3233/JPD-212920 · DOI
  35. Grealish, 2015, Monosynaptic tracing using modified rabies virus reveals early and extensive circuit integration of human embryonic stem cell-derived neurons, Stem Cell Rep., 4, 975, 10.1016/j.stemcr.2015.04.011 · DOI
  36. Steinbeck, 2015, Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model, Nat. Biotechnol., 33, 204, 10.1038/nbt.3124 · DOI
  37. Tiklová, 2020, Single cell transcriptomics identifies stem cell-derived graft composition in a model of Parkinson's disease, Nat. Commun., 11, 2434, 10.1038/s41467-020-16225-5 · DOI
  38. Yang, 2022, Therapeutic functions of astrocytes to treat alpha-synuclein pathology in Parkinson's disease, Proc. Natl. Acad. Sci. USA, 119
  39. Christensen, 2018, Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway, Brain Res. Bull., 139, 167, 10.1016/j.brainresbull.2018.02.010 · DOI
  40. Glud, 2017, A fiducial skull marker for precise MRI-based stereotaxic surgery in large animal models, J. Neurosci. Methods, 285, 45, 10.1016/j.jneumeth.2017.04.017 · DOI
  41. Lillethorup, 2018, Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs, Exp. Neurol., 303, 142, 10.1016/j.expneurol.2018.02.005 · DOI

Cited by

Sorted by citations

See all 158

Metadata

Authors
Kirkeby, A., Nelander, J., Hoban, D. B., Rogelius, N., Bjartmarz, H., Storm, P., Fiorenzano, A., Adler, A. F., Vale, S., Mudannayake, J., Zhang, Y., Cardoso, T., Mattsson, B., Landau, A. M., Glud, A. N., Sørensen, J. C., Lillethorup, T. P., Lowdell, M., Carvalho, C., Bain, O., van Vliet, T., Lindvall, O., Björklund, A., Harry, B., Cutting, E., Widner, H., Paul, G., Barker, R. A., & Parmar, M.
Venue
Cell Stem Cell
Publisher
Elsevier BV
Published
2023-10
Volume
30
Issue
10
Pages
1299-1314.e9
ISSN
1934-5909
DOI
10.1016/j.stem.2023.08.014
Cited by
158
References
4
Language
en
Licence
Funders
  • Knut and Alice Wallenberg Foundation
  • Swedish Research Council (2016-00873, 2021-00661)
  • New York Stem Cell Foundation (NYSCF-R-I37)
  • Lundbeck Foundation (R211-2015-3784, R303-2018-3058)
  • European Union (FP7 HEALTH-F4-2013-602278, 874758)
  • Novo Nordisk Foundation (NNF18OC0030286, NNF21CC0073729)
  • Novo Nordisk A/S
  • European Research Council (771427)
  • Parkinsonfonden
  • Innovation Fund
  • Hjärnfonden (FO2019-0301)
  • Swedish Foundation for Strategic Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review